Filing Flows › Lemaitre Vascular (LMAT) › Q3 2026 › vs Q3 2025
Lemaitre Vascular (LMAT) Q3 2026 vs Q3 2025 (year over year)
Lemaitre Vascular's revenue rose $6.9M (+11%) from $61.0M in Q3 2025 to $68.0M in Q3 2026. Gross margin 71.7% against 75.3% (-3.6 pts).
Lemaitre Vascular, Q3 2026: revenue $68.0M (+11% year over year), operating margin 26.0%, net earnings $15.0M, operating cash flow $22.0M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 71.7% | 75.3% | -3.6 pts |
| Operating margin | 26.0% | 33.3% | -7.2 pts |
| Net margin | 22.1% | 28.4% | -6.3 pts |
| Free cash flow margin | 28.9% | 43.4% | -14.5 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $68.0M | $61.0M | $6.9M | +11% |
| Gross profit | $48.7M | $46.0M | $2.8M | +6% |
| Cost of revenue | $19.3M | $15.1M | $4.2M | +28% |
| Other income, net | $2.0M | $2.3M | −$282K | -12% |
| Operating profit | $17.7M | $20.3M | −$2.6M | -13% |
| Operating expenses | $31.0M | $25.6M | $5.4M | +21% |
| Pre-tax earnings | $19.7M | $22.6M | −$2.9M | -13% |
| Research & development | $4.4M | $3.0M | $1.5M | +49% |
| Sales & marketing | $14.5M | $11.9M | $2.6M | +22% |
| General & admin | $12.1M | $10.8M | $1.3M | +12% |
| Net earnings | $15.0M | $17.4M | −$2.3M | -13% |
| Income tax | $4.7M | $5.2M | −$561K | -11% |
| Depreciation & amortization | $2.9M | $2.6M | $272K | +10% |
| Share-based compensation | $2.0M | $1.7M | $289K | +17% |
| Working capital & other | $2.1M | $7.0M | −$5.0M | -71% |
| Operating cash flow | $22.0M | $28.8M | −$6.8M | -24% |
| Free cash flow (OCF − capex) | $19.7M | $26.5M | −$6.8M | -26% |
| Capital expenditures | $2.3M | $2.3M | $52K | +2% |
Questions
How much did Lemaitre Vascular's revenue grow year over year in Q3 2026?
Lemaitre Vascular's revenue rose $6.9M (+11%) from $61.0M in Q3 2025 to $68.0M in Q3 2026. Gross margin 71.7% against 75.3% (-3.6 pts).